Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › About Us › Our Staff › Andrew P. Han

Andrew P. Han

Editor
Phone Number
+1-212-651-5640
Email
[email protected]

Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.

Articles Authored by Andrew P. Han

Apr 02, 2021

Illumina Parries FTC Challenge to Grail Acquisition With Deals for Competing Customers

Premium

The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment.

Feb 25, 2021

Adaptive Biotechnologies Touts New Era of T Cell-Based Dx With T-Detect COVID Launch

Premium

Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.

Feb 25, 2021

German Nucleic Acid Sample Prep Startup Rides COVID-19 Testing, Automation Waves

Premium

The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.

Jan 11, 2021

Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

Nov 24, 2020

Startup Angstrom Bio Plans Saliva-Based COVID-19 Nucleic Acid Test on Nanopore Sequencing Platform

Premium

Angstrom Bio is developing a rapid, scalable coronavirus test that uses nanopore sequencing to detect barcoded PCR products.

Nov 11, 2020

Adaptive Biotechnologies Prepares to Launch T Cell-Based COVID-19 Test

Premium

Adaptive is rebranding its immunoSeq Dx assay as T-Detect and plans to submit for an EUA for a COVID-19 T-Cell response test by the end of the year.

Sep 21, 2020

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

Premium

Illumina thinks the next-generation sequencing cancer testing market will grow to $75 billion over the next 15 years, driven by screening.

Aug 17, 2020

Bionano Genomics Expecting Clinical Validation Studies to Drive Platform Adoption

Premium

The firm is hoping that researcher-generated data will soon be published in peer-reviewed papers, while it weathers the COVID-19 pandemic.

Aug 07, 2020

Illumina Sees Expanding Sequencing Market in COVID-19 Response, Despite Short-Term Woes

Premium

The sequencing firm said infectious disease research, diagnostics, screening, and surveillance could all increase demand for its NGS products.

Aug 05, 2020

Fulgent Genetics Touts Returns on COVID-19 Testing Investment

Premium

Company officials credited investments in information technology, as well as R&D for RT-PCR-based tests, with driving up the firm's billable testing numbers.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.